| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Beta-tricalcium phosphate (β-TCP) has a reliable long carrier as a bone substituent used in the clinic. In the present study, we focused on the immuno-stimulating potential of β-TCP, and carried out research toward the development of β-TCP as a novel vaccine adjuvant, and obtained the following findings; 1) β-TCP activates and induces maturation of macrophages (MΦ) and dendritic cells (DC). 2) β-TCP activates inflammasomes in MΦ and DC in the presence of ligands for Toll-like receptors (TLR). 3) β-TCP and TLR ligand synergistically enhances antitumor effect of a cancer vaccine in a mouse tumor model. These findings indicate that the potential of β-TCP as a novel vaccine adjuvant.
|
